抗白介素药物对COVID-19伴细胞因子释放综合征患者的效果(COV-AID):析因随机对照试验
COV-AID是一项在比利时16家医院进行的析因随机对照试验,纳入342例COVID-19伴低氧性呼吸衰竭和细胞因子释放综合征征象的住院患者,评估IL-1阻断(阿那白滞素)和IL-6阻断(托珠单抗或司妥昔单抗)能否缩短临床改善时间。死亡率、严重不良事件和严重感染在各组间相似。
要点
- IL-1或IL-6阻断均未缩短COVID-19伴细胞因子释放综合征患者的临床改善时间。
- 研究纳入低SOFA评分和低基线死亡风险患者,死亡率组间无差异。
- 严重不良事件和严重感染发生率在治疗组间相似。
核心结论
- 靶向IL-1或IL-6的药物未缩短COVID-19伴低氧性呼吸衰竭、低SOFA评分和低基线死亡风险患者的临床改善时间。
研究设计与样本
- 前瞻性、多中心、开放标签、随机对照试验,在比利时16家医院进行,采用2×2析因设计。
- 共随机分配342例患者:IL-1阻断组112例 vs 无IL-1阻断组230例;IL-6阻断组227例(托珠单抗114例,司妥昔单抗113例) vs 无IL-6阻断组115例。
- 纳入标准包括确诊COVID-19症状6-16天、PaO2:FiO2<350 mmHg(室内空气)或<280 mmHg(吸氧)以及血清细胞因子释放综合征征象。
- 主要终点为随机化至6分类序数量表增加至少2分或活着出院的时间,在意向性治疗人群中分析。
- 患者中位年龄65岁(IQR 54-73),男性265例(77%),中位SOFA评分3分(2-4)。
主要发现
- 研究期间55例患者死亡,治疗组间死亡率无差异证据。
- 严重不良事件和严重感染发生率在各研究组间相似。
临床怎么用
- 对于COVID-19伴低氧性呼吸衰竭和细胞因子释放综合征征象但SOFA评分低、基线死亡风险低的患者,不应常规使用IL-1或IL-6阻断来缩短临床改善时间。
局限性
- 研究为开放标签设计,可能影响主观终点的评估。
- 研究人群限于低SOFA评分和低基线死亡风险患者,结论不能外推至重症或高死亡风险人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infections with SARS-CoV-2 continue to cause significant morbidity and mortality. Interleukin (IL)-1 and IL-6 blockade have been proposed as therapeutic strategies in COVID-19, but study outcomes have been conflicting. We sought to study whether blockade of the IL-6 or IL-1 pathway shortened the time to clinical improvement in patients with COVID-19, hypoxic respiratory failure, and signs of systemic cytokine release syndrome. METHODS: We did a prospective, multicentre, open-label, randomised, controlled trial, in hospitalised patients with COVID-19, hypoxia, and signs of a cytokine release syndrome across 16 hospitals in Belgium. Eligible patients had a proven diagnosis of COVID-19 with symptoms between 6 and 16 days, a ratio of the partial pressure of oxygen to the fraction of inspired oxygen (PaO2:FiO2) of less than 350 mm Hg on room air or less than 280 mm Hg on supplemental oxygen, and signs of a cytokine release syndrome in their serum (either a single ferritin measurement of more than 2000 μg/L and immediately requiring high flow oxygen or mechanical ventilation, or a ferritin concentration of more than 1000 μg/L, which had been increasing over the previous 24 h, or lymphopenia below 800/mL with two of the following criteria: an increasing ferritin concentration of more than 700 μg/L, an increasing lactate dehydrogenase concentration of more than 300 international units per L, an increasing C-reactive protein concentration of more than 70 mg/L, or an increasing D-dimers concentration of more than 1000 ng/mL). The COV-AID trial has a 2 × 2 factorial design to evaluate IL-1 blockade versus no IL-1 blockade and IL-6 blockade versus no IL-6 blockade. Patients were randomly assigned by means of permuted block randomisation with varying block size and stratification by centre. In a first randomisation, patients were assigned to receive subcutaneous anakinra once daily (100 mg) for 28 days or until discharge, or to receive no IL-1 blockade (1:2). In a second randomisation step, patients were allocated to receive a single dose of siltuximab (11 mg/kg) intravenously, or a single dose of tocilizumab (8 mg/kg) intravenously, or to receive no IL-6 blockade (1:1:1). The primary outcome was the time to clinical improvement, defined as time from randomisation to an increase of at least two points on a 6-category ordinal scale or to discharge from hospital alive. The primary and supportive efficacy endpoints were assessed in the intention-to-treat population. Safety was assessed in the safety population. This study is registered online with ClinicalTrials.gov (NCT04330638) and EudraCT (2020-001500-41) and is complete. FINDINGS: Between April 4, and Dec 6, 2020, 342 patients were randomly assigned to IL-1 blockade (n=112) or no IL-1 blockade (n=230) and simultaneously randomly assigned to IL-6 blockade (n=227; 114 for tocilizumab and 113 for siltuximab) or no IL-6 blockade (n=115). Most patients were male (265 [77%] of 342), median age was 65 years (IQR 54-73), and median Systematic Organ Failure Assessment (SOFA) score at randomisation was 3 (2-4). All 342 patients were included in the primary intention-to-treat analysis. The estimated median time to clinical improvement was 12 days (95% CI 10-16) in the IL-1 blockade group versus 12 days (10-15) in the no IL-1 blockade group (hazard ratio [HR] 0·94 [95% CI 0·73-1·21]). For the IL-6 blockade group, the estimated median time to clinical improvement was 11 days (95% CI 10-16) versus 12 days (11-16) in the no IL-6 blockade group (HR 1·00 [0·78-1·29]). 55 patients died during the study, but no evidence for differences in mortality between treatment groups was found. The incidence of serious adverse events and serious infections was similar across study groups. INTERPRETATION: Drugs targeting IL-1 or IL-6 did not shorten the time to clinical improvement in this sample of patients with COVID-19, hypoxic respiratory failure, low SOFA score, and low baseline mortality risk. FUNDING: Belgian Health Care Knowledge Center and VIB Grand Challenges program.
引用
- Declercq J, Van Damme KFA, De Leeuw E, et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respir Med. 2021. PMID: 34756178. doi:10.1016/S2213-2600(21)00377-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。